Arvinas, Inc
Symbol: ARVN (NASDAQ)
7.81
▼ (-2.44%) -0.195
Company Description:
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Key Stats
- Today's Open: $7.96
- Today's High: $8.095
- Today's Low: $7.793
- Today's Volume: 1.32M
- Yesterday Close: $8
- Yesterday High: $8.105
- Yesterday Low: $7.81
- Yesterday Volume: 1.21M
- Last Min Volume: 500
- Last Min High: $7.805
- Last Min Low: $7.805
- Last Min VWAP: $7.805
Company Profile
- Name: Arvinas, Inc
- Website: https://www.arvinas.com
- Listed Date: 2018-09-27
- Location: NEW HAVEN, CT
- Market Status: Active
- CIK Number: 0001655759
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $582.94M
- Round Lot: 100
- Outstanding Shares: 73.42M
- Asset Type: CS
RECENT FILINGS FOR ARVN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-22 | SCHEDULE 13D/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-08 | 8-K | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-07-09 | 8-K | View |
| 2025-06-30 | 8-K | View |
| 2025-06-30 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-23 | 144 | View |
| 2025-06-18 | 4 | View |
| 2025-06-16 | SCHEDULE 13D | View |
| 2025-06-13 | 8-K | View |
Latest News on ARVN